Table 1.

Clinical characteristics and in vivo patient-derived tumor take rate

Primary tumor samples (n = 58)
Patient clinical characteristics
All collectedGrowing on nude mice (n = 35)
ParametersClassNumberFrequency (%)NumberFrequency (%)In vivo tumor take rate (%)
Gender
Female3662.12262.961.1
Male2237.91337.159.1
Age
<50 y813.8720.087.5
>50 and <60 y1424.1822.957.1
>60 and <70 y1322.4514.338.5
>70 and <80 y1729.31028.658.8
>80 y610.3514.383.3
pT - primary tumor status
Unknown0000NA
pTx0000NA
pTis23.4000
pT111.7000
pT2813.838.637.5
pT33662.12571.469.4
pT41119.0720.063.6
pN - lymp node status
Unknown0000NA
pNx (not assessable)0000NA
pN02746.5925.733.3
pN+3153.52674.383.9
pM - distant metastasis status
Unknown0000NA
pMx (not assessable)23.412.950.0
pM03560.32057.157.1
pM12136.21440.066.7
Stage
Unknown23.512.950.0
023.5000
I712.125.728.6
II1220.7514.341.7
III1424.11337.192.9
IV2136.21440.066.7
CEA dosage before surgery (ng/mL)
Unknown1932.81234.363.2
<62136.2925.742.9
>61831.01440.077.8
Primary tumor location
Proximal colon2034.51234.360.0
Distal colon2034.51440.070.0
Rectum1831.0925.750.0
Metastasis and carcinosis tumor samples (n = 27)
Patient clinical characteristics
All collectedGrowing on nude mice (n = 19)
ParametersClassNumberFrequency (%)NumberFrequency (%)In vivo tumor take rate (%)
Gender
Female1659.31157.968.7
Male1140.7842.172.7
Age
<50 y311.115.333.3
>50 and <60 y829.6526.362.5
>60 and <70 y933.3736.877.8
>70 and <80 y518.5421.080.0
>80 y27.4210.5100
pT - primary tumor status
Unknown27.400.00.0
pTx13.715.3100.0
pTis00.000.0NA
pT100.000.0NA
pT227.4210.5100.0
pT31037.0842.180.0
pT41244.4842.166.7
pN - lymp node status
Unknown27.400.00.0
pNx (not assessable)414.8315.875.0
pN0622.2421.066.7
pN+1555.61263.280.0
pM - distant metastasis status
Unknown27.400.00.0
pMx (not assessable)00.000.0NA
pM027.4210.5100.0
pM12385.21789.573;9
Stage
Unknown27.400.00.0
000.000.0NA
I00.000.0NA
II27.4210.5100.0
III00.000.0NA
IV2385.21789.573.9
CEA dosage before surgery (ng/mL)
Unknown933.3947.4100.0
<6311.1210.566.7
>61555.6842.153.3
Primary tumor location
Proximal colon933.3631.666.7
Distal colon1659.31263.275.0
Rectum27.415.350.0
Parameters associated with in vivo tumor take rateNo growthGrowth
Probabilities
pN+ and CEA ≥ 6 and proximal or distal colon0.00001.0000
pN+ and CEA ≥ 6 and rectum0.12500.8750
pN+ and CEA < 6 and pM00.16670.8333
pN0 and rectum0.87500.1250
Numbers
pN+ and CEA ≥ 6 and proximal or distal colon021
pN+ and CEA ≥ 6 and rectum17
pN+ and CEA < 6 and pM015
pN0 and rectum71

NOTE: Patient clinical characteristics and associated in vivo tumor take rate of (i) all collected samples and (ii) xenograft models established on nude mice for primary tumor samples (upper table) and metastasis and carcinosis tumor samples (middle table). Metastasis metastatic samples include hepatic, splenic, and mesenteric lymph node metastasis.

Abbreviations: pTx, primary tumor cannot be assesse;. pTis, primary in situ tumor; pT1, tumor invades mucosa and submucosa; pT2, tumor invades muscularis propria; pT3, tumor invades serosa, subserosa, or pericolic fat tissues; pT4, tumor invades peritoneal cavity through serosa or expands to other proximal organs through serosa; pN0, N0, no positive regional lymph nodes; pN+, at least 1 positive regional lymph node; pM0, at the stage of primary tumor evaluation, no distant metastasis; pM1, at the stage of primary tumor evaluation, presence of distant metastasis.

Influencing parameter associations significantly correlated with tumor take rate as determined by recursive partitioning (bottom table). The probabilities of no growth/growth and the effective for each signature are presented.